Literature DB >> 25027318

Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology.

Megha Maheshwari1, Shashi Shekhar1, Brijesh Kumar Singh1, Imran Jamal1, Naman Vatsa1, Vipendra Kumar1, Ankit Sharma1, Nihar Ranjan Jana2.   

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder caused by abnormal expansion of CAG repeats in the gene encoding huntingtin. Mutant huntingtin undergoes proteolytic processing and its N-terminal fragment containing polyglutamine repeat accumulates as inclusion not only in nucleus but also in cytoplasm and neuronal processes. Here, we demonstrate that removal of ubiquitin ligase Ube3a selectively from HD mice brain resulted in accelerated disease phenotype and shorter lifespan in comparison with HD mice. The deficiency of Ube3a in HD mice brain also caused significant increase in global aggregates load, and these aggregates were less ubiquitinated when compared with age-matched HD mice. These Ube3a-maternal deficient HD mice also showed drastic reduction of DARPP-32, a dopamine-regulated phoshphoprotein in their striatum. These results emphasize the crucial role of Ube3a in the progression of HD and its immense potential as therapeutic target.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25027318     DOI: 10.1093/hmg/ddu343

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  10 in total

1.  Genome-wide In Vivo CNS Screening Identifies Genes that Modify CNS Neuronal Survival and mHTT Toxicity.

Authors:  Mary H Wertz; Mollie R Mitchem; S Sebastian Pineda; Lea J Hachigian; Hyeseung Lee; Vanessa Lau; Alex Powers; Ruth Kulicke; Gurrein K Madan; Medina Colic; Martine Therrien; Amanda Vernon; Victoria F Beja-Glasser; Mudra Hegde; Fan Gao; Manolis Kellis; Traver Hart; John G Doench; Myriam Heiman
Journal:  Neuron       Date:  2020-01-30       Impact factor: 17.173

2.  Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.

Authors:  Brijesh Kumar Singh; Naman Vatsa; Vinod K Nelson; Vipendra Kumar; Shashi Shekhar Kumar; Subhash C Mandal; Mahadeb Pal; Nihar Ranjan Jana
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

3.  RNF166 Determines Recruitment of Adaptor Proteins during Antibacterial Autophagy.

Authors:  Robert J Heath; Gautam Goel; Leigh A Baxt; Jason S Rush; Vishnu Mohanan; Geraldine L C Paulus; Vijay Jani; Kara G Lassen; Ramnik J Xavier
Journal:  Cell Rep       Date:  2016-11-22       Impact factor: 9.423

Review 4.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

Review 5.  Strategies to Investigate Ubiquitination in Huntington's Disease.

Authors:  Karen A Sap; Eric A Reits
Journal:  Front Chem       Date:  2020-06-11       Impact factor: 5.221

6.  NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease.

Authors:  Katharine M von Herrmann; Lucas A Salas; Eileen M Martinez; Alison L Young; Joseph M Howard; Mary S Feldman; Brock C Christensen; Owen M Wilkins; Stephen L Lee; William F Hickey; Matthew C Havrda
Journal:  NPJ Parkinsons Dis       Date:  2018-08-15

Review 7.  Promising drug targets and associated therapeutic interventions in Parkinson's disease.

Authors:  Sachchida Nand Rai; Payal Singh; Ritu Varshney; Vivek K Chaturvedi; Emanuel Vamanu; M P Singh; Brijesh Kumar Singh
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

8.  Praja1 ubiquitin ligase facilitates degradation of polyglutamine proteins and suppresses polyglutamine-mediated toxicity.

Authors:  Baijayanti Ghosh; Susnata Karmakar; Mohit Prasad; Atin K Mandal
Journal:  Mol Biol Cell       Date:  2021-06-23       Impact factor: 4.138

9.  Pridopidine activates neuroprotective pathways impaired in Huntington Disease.

Authors:  Michal Geva; Rebecca Kusko; Holly Soares; Kevin D Fowler; Tal Birnberg; Steve Barash; Avia Merenlender -Wagner; Tania Fine; Andrew Lysaght; Brian Weiner; Yoonjeong Cha; Sarah Kolitz; Fadi Towfic; Aric Orbach; Ralph Laufer; Ben Zeskind; Iris Grossman; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2016-07-27       Impact factor: 6.150

Review 10.  Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin.

Authors:  Annarita Fiorillo; Veronica Morea; Gianni Colotti; Andrea Ilari
Journal:  J Pers Med       Date:  2021-12-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.